I've changed my mind about the Core 2 Duo smartwatch and Pebble's return
Table of Contents
Table of Contents What changed? It's now a real product We don't need it, but we also do need it Will I actually wear it?
What have I done? I've gone back on something I wrote with a fire in my belly and poison on my tongue about the new Pebble smartwatch, the Core Devices Core 2 Duo. I've not really reversed my position on it, but have been convinced enough to place a pre-order, which back in March seemed like a ridiculous thing to do. Here's what changed my mind about the Core 2 Duo.
What changed?
My overall opinion of the basic new Pebble, the Core 2 Duo, hasn't altered. Practically every other smartwatch you can buy today will be more technically impressive, more useful, more feature packed, better looking, and more durable. It's why I don't feel like a fraud saying all those awful things about it before, in light of what I've now gone and done, because I know I'm still right.
Recommended Videos
Yet, I've put down $150 (and whatever horrendous import charges I'll face upon delivery) for a Core 2 Duo. I am too late to get a model in the first wave, and will have to wait until July for delivery. What has convinced me it's worth all the money and wait? A big part of it was seeing the smartwatch in action for the first time.
Pebble and Core Devices founder Eric Migicovsky demonstrated an early prototype of the Core 2 Duo during the first edition of his Tick Talk podcast on YouTube recently, and although it was hardly an extensive, in-depth look, it was enough to see the smartwatch is not only real, but a true work in progress. Before this, all we had was a few rendered images, a spec sheet, and Migivosky's word. It wasn't enough to convince me to buy.
It's now a real product
Seeing the Core 2 Duo (all taped up because it's a development mule) on Migicovsky's wrist made the project come alive. I didn't doubt it was real before, but I'm not enough of a Pebble devotee to throw $150 in his direction because of a few rendered images and a promise to deliver.
I was also sold by the the way the Core 2 Duo was presented. Migicovsky chose to demo it despite the smartwatch still being a work in progress, which shows considerable confidence, but he was still honest and open about the limitations. He did so sat at a desk in a homemade studio, and I appreciated the friendly presentation a lot. No-one was screaming how it's the best thing ever, and nobody was pompously 'selling' its functionality (or general lack-of) like it would change the world either.
It's a simple piece of tech presented simply, and I really liked the conversational, yet still passionate approach. Other companies would have made a lot more fuss about showing their product off, even in the same, far-from-sale-ready state as Migicovsky's Core 2 Duo. Seeing it work, on a wrist, and spoken about honestly (and free from a marketing team's influence) meant it took on its own life. It became a product I wanted to support.
We don't need it, but we also do need it
Support is a key word in my personal decision to pre-order the Core 2 Duo. I absolutely stand by what I said about it dripping in mostly misplaced nostalgia, particularly in any appeal from the design. I owned an original Pebble so I know it's not going to change my life. If I want to avoid notifications or not worry about battery life, I've got plenty of non-smart watches waiting to be worn.
We don't need it at all, because far better examples of high quality wrist wear exist, connected or otherwise. Yet, what a shame it would be if small brands — even ones with valuable name recognition like Pebble and Migicovsky — couldn't produce and sell passion projects like the Core 2 Duo. For every massive brand selling exciting new tech, there really should be smaller, less well-known ones doing the same. But without our support, they won't get very far.
Not all of them deserve our attention, and flashy presentations don't guarantee a good product (yes, Humane, I'm talking about you), but there does come a time when you feel confident enough to spend your hard-earned on something new. It does look like the Core 2 Duo is really real, on its way very soon, with the expected look and functionality. It's not that I seriously doubted any of this before. I didn't give it any consideration at all, because a few digital images and a promise or two about the future would never encourage me to do so. It all felt as empty as buying an NFT.
Will I actually wear it?
If I've pre-ordered the Core 2 Duo to support the project and what it means for wearable tech, does that mean I haven't bought it to wear? It's definitely not the driving force behind my purchase. The combination of my Apple Watch Series 10, Oura Ring 4, and Ray-Ban Meta smartglasses arguably do everything I want from wearable tech today.
I'll definitely give it a try when it arrives, and who knows, perhaps I'll love the retro software and surely-its-made-for-kids style? Either way, I've re-examined my position on the Core 2 Duo and I'm very pleased to have done so, even though it's not for the reasons some others championed it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
an hour ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's Why Globant S.A. (GLOB) Has Trembled More Than 55% This Year
Globant S.A. (NYSE:GLOB) is one of the 11 Best Tech Stocks to Buy On the Dip. The company released its Q1 2025 results on May 15. Globant S.A. (NYSE:GLOB) missed revenue and EPS estimates causing the stock to dip. It posted a revenue of $611.09 million, reflecting 7% growth. However, this was below the market consensus by $10.37 million. The EPS of $1.50 also missed estimates by $0.08. On May 16, Arvind Ramnani analyst at Piper Sandler downgraded Globant S.A. (NYSE:GLOB) from Buy to Hold, while also adjusting the price target from $154 to $116. The analyst noted they had already estimated the macro headwinds, which impacted the revenue growth thereby reducing its estimates. A close-up of an experienced game engineer's hands typing a complex code on a laptop. Impax US Sustainable Economy Fund mentioned Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter. The fund noted that the company delivered satisfactory results driven by broad demand through various industry verticals and also witnessed revenue growth in new markets. Despite the satisfactory growth, the stock has trembled more than 55.87% on a year-to-date basis mainly due to a complex macroeconomic environment impacting customer spending. The fund anticipates the economic pressure to impact the revenue projections. Management of Globant S.A. (NYSE:GLOB) anticipates second-quarter revenue to be at least $612.0 million, reflecting 4.2% year-over-year growth. Impax US Sustainable Economy Fund stated the following regarding Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter: 'Globant S.A. (NYSE:GLOB) (Information Technology) is a software solutions provider helping to enhance productivity and drive increasing digital infrastructure in the transition to a more sustainable economy. The stock was down despite delivering satisfactory results, due to broad demand across multiple industry verticals and significant revenue growth in new markets. However, political volatility and macroeconomic pressures in Latin America are expected to affect demand, resulting in slightly lower revenue projections for the upcoming fiscal year.' While we acknowledge the potential of GLOB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
